- Home
- BNR vs HOWL Comparison
BNR vs HOWL Comparison
Compare BNR & HOWL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BNR
- HOWL
- Stock Information
- Founded
- BNR 2014
- HOWL 2017
- Country
- BNR China
- HOWL United States
- Employees
- BNR N/A
- HOWL N/A
- Industry
- BNR Medical Specialities
- HOWL Biotechnology: Pharmaceutical Preparations
- Sector
- BNR Health Care
- HOWL Health Care
- Exchange
- BNR Nasdaq
- HOWL Nasdaq
- Market Cap
- BNR 61.7M
- HOWL 62.4M
- IPO Year
- BNR 2020
- HOWL 2021
- Fundamental
- Price
- BNR $5.66
- HOWL $1.23
- Analyst Decision
- BNR
- HOWL Strong Buy
- Analyst Count
- BNR 0
- HOWL 2
- Target Price
- BNR N/A
- HOWL $9.50
- AVG Volume (30 Days)
- BNR 5.3K
- HOWL 284.6K
- Earning Date
- BNR 03-27-2025
- HOWL 05-02-2025
- Dividend Yield
- BNR N/A
- HOWL N/A
- EPS Growth
- BNR N/A
- HOWL N/A
- EPS
- BNR N/A
- HOWL N/A
- Revenue
- BNR $72,832,704.00
- HOWL $3,386,000.00
- Revenue This Year
- BNR $52.90
- HOWL N/A
- Revenue Next Year
- BNR $48.35
- HOWL $34.17
- P/E Ratio
- BNR N/A
- HOWL N/A
- Revenue Growth
- BNR N/A
- HOWL N/A
- 52 Week Low
- BNR $0.57
- HOWL $1.03
- 52 Week High
- BNR $8.99
- HOWL $6.89
- Technical
- Relative Strength Index (RSI)
- BNR 40.71
- HOWL 41.12
- Support Level
- BNR $4.41
- HOWL $1.03
- Resistance Level
- BNR $6.33
- HOWL $1.29
- Average True Range (ATR)
- BNR 0.54
- HOWL 0.11
- MACD
- BNR -0.16
- HOWL -0.01
- Stochastic Oscillator
- BNR 35.82
- HOWL 37.04
About BNR Burning Rock Biotech Limited
Burning Rock Biotech Ltd is a cancer diagnostics company. It is a NGS-based cancer therapy selection company. Its cancer therapy selection platform is built upon advanced proprietary technologies, comprehensive portfolio of products and a two-pronged market-driven commercial infrastructure addressing both larger hospitals through our in-hospital model and smaller hospitals through our central laboratory model. It had three operating segments, including Central laboratory business, In-hospital business and Pharma research and development services. It generates the majority of its revenue from Central laboratory business. Its products are Pan-HEME, OncoScreen-WES, brPROPHET, OncoScreen Plus, and others.
About HOWL Werewolf Therapeutics Inc.
Werewolf Therapeutics Inc is a biopharmaceutical company pioneering the development of therapeutics engineered to stimulate the body's immune system for the treatment of cancer. It is leveraging its proprietary PREDATOR platform to design conditionally activated molecules that stimulate both adaptive and innate immunity with the goal of addressing the limitations of conventional proinflammatory immune therapies. Its INDUKINE molecules are intended to remain inactive in peripheral tissue yet activate selectively in the tumor microenvironment or TME.